Rafferty Asset Management LLC Buys 23,314 Shares of Agios Pharmaceuticals, Inc. $AGIO

Key Points

• Rafferty Asset Management LLC increased its stake in Agios Pharmaceuticals by 33.2%, owning 93,627 shares worth approximately $2.74 million as of the latest SEC filing.
• Agios Pharmaceuticals reported a quarterly loss of ($1.93) per share, missing the consensus estimate, but generated revenue of $12.50 million, surpassing analyst expectations.
• Analysts have mixed views on Agios Pharmaceuticals, with target price revisions ranging from $51.00 to $65.00, and an average rating of "Moderate Buy" based on six buy and two hold ratings.

Rafferty Asset Management LLC increased its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 33.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 93,627 shares of the biopharmaceutical company's stock after purchasing an additional 23,314 shares during the quarter. Rafferty Asset Management LLC owned approximately 0.16% of Agios Pharmaceuticals worth $2,743,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of AGIO. GF Fund Management CO. LTD. bought a new stake in shares of Agios Pharmaceuticals in the fourth quarter worth $39,000. CWM LLC lifted its holdings in Agios Pharmaceuticals by 150.2% in the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock valued at $49,000 after buying an additional 996 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Agios Pharmaceuticals by 16.2% in the first quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company's stock valued at $105,000 after buying an additional 499 shares during the period. GAMMA Investing LLC lifted its holdings in Agios Pharmaceuticals by 9,296.6% in the first quarter. GAMMA Investing LLC now owns 8,175 shares of the biopharmaceutical company's stock valued at $240,000 after buying an additional 8,088 shares during the period. Finally, Commerce Bank acquired a new position in Agios Pharmaceuticals in the first quarter valued at $240,000.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 1,780 shares of the company's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total value of $59,701.20. Following the completion of the sale, the chief financial officer directly owned 30,049 shares of the company's stock, valued at approximately $1,007,843.46. This represents a 5.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Tsveta Milanova sold 2,770 shares of the company's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total transaction of $92,905.80. Following the completion of the sale, the insider directly owned 26,122 shares of the company's stock, valued at $876,131.88. The trade was a 9.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 57,448 shares of company stock worth $2,026,141 in the last ninety days. 4.30% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Trading Down 11.0%

Shares of AGIO traded down $4.48 on Thursday, reaching $36.13. The company's stock had a trading volume of 3,132,082 shares, compared to its average volume of 532,208. Agios Pharmaceuticals, Inc. has a twelve month low of $23.42 and a twelve month high of $62.58. The stock has a market capitalization of $2.10 billion, a PE ratio of 3.28 and a beta of 0.87. The firm has a fifty day moving average of $37.53 and a 200-day moving average of $33.19.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.19). Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%.The business had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.46 million. As a group, equities analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on AGIO. Bank of America dropped their target price on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. HC Wainwright restated a "buy" rating and issued a $56.00 target price on shares of Agios Pharmaceuticals in a report on Thursday. Scotiabank dropped their target price on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating on the stock in a report on Monday, July 28th. Finally, Wall Street Zen lowered shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, May 19th. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $56.00.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.